203 related articles for article (PubMed ID: 35499207)
41. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
[TBL] [Abstract][Full Text] [Related]
42. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous T-cell lymphoma (mycosis fungoides).
Lorincz AL
Lancet; 1996 Mar; 347(9005):871-6. PubMed ID: 8622396
[No Abstract] [Full Text] [Related]
44. [Cutaneous T-cell lymphoma].
Dippel E; Gellrich S; Klemke CD; Goerdt S; Sterry W
J Dtsch Dermatol Ges; 2003 Dec; 1(12):965-80; quiz 981-2. PubMed ID: 16285650
[No Abstract] [Full Text] [Related]
45. [Current therapeutic options in Mycosis fungoides and Sézary syndrome].
Albrecht JD; Nicolay JP
Hautarzt; 2022 Jan; 73(1):75-85. PubMed ID: 34988613
[TBL] [Abstract][Full Text] [Related]
46. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; A Wilcox R
Am J Hematol; 2021 Oct; 96(10):1313-1328. PubMed ID: 34297414
[TBL] [Abstract][Full Text] [Related]
48. Clinical Insights and Emerging Strategies in Managing Cutaneous T-Cell Lymphoma.
Patrone CC; Geskin LJ
J Drugs Dermatol; 2017 May; 16(5):405-412. PubMed ID: 29028854
[TBL] [Abstract][Full Text] [Related]
49. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Hautarzt; 2019 Oct; 70(10):815-830. PubMed ID: 31511903
[TBL] [Abstract][Full Text] [Related]
50. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
51. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Pathologe; 2020 Feb; 41(1):79-94. PubMed ID: 31932947
[TBL] [Abstract][Full Text] [Related]
52. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
53. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
[TBL] [Abstract][Full Text] [Related]
54. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
Horna P; Moscinski LC; Sokol L; Shao H
Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
[TBL] [Abstract][Full Text] [Related]
55. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
56. Lymphoma-associated hemophagocytic syndrome (LAHS) in advanced-stage mycosis fungoides/Sézary syndrome cutaneous T-cell lymphoma.
Blom A; Beylot-Barry M; D'Incan M; Laroche L
J Am Acad Dermatol; 2011 Aug; 65(2):404-410. PubMed ID: 21550694
[TBL] [Abstract][Full Text] [Related]
57. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
Horwitz SM; Olsen EA; Duvic M; Porcu P; Kim YH
J Natl Compr Canc Netw; 2008 Apr; 6(4):436-42. PubMed ID: 18433609
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2016 Jan; 91(1):151-65. PubMed ID: 26607183
[TBL] [Abstract][Full Text] [Related]
59. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
Beltraminelli H
Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
[TBL] [Abstract][Full Text] [Related]
60. Clinical Outcomes of COVID-19 in Mycosis Fungoides and Sezary Syndrome.
Levy Yurkovski I; Rokach L; Melamed G; Alapi H; Gazit S; Patalon T; Tadmor T
Acta Haematol; 2023; 146(6):496-503. PubMed ID: 37517402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]